8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Biogen reports Q2 revenue growth, cuts 2026 EPS guidance
Filed with the SEC on · Summarized by InvestorsBot
Biogen reported second-quarter 2026 revenue of $2.736 billion on July 29, up 3% year over year, while GAAP diluted EPS fell to $0.66 from $4.33 and non-GAAP EPS declined to $3.60 from $5.47. The company raised its underlying non-GAAP EPS outlook to $15.85-$16.85 but lowered reported 2026 guidance to $12.00-$13.00 because of about $3.00 per share in acquired IPR&D and milestone charges and approximately $0.85 of dilution from its May 14 Apellis acquisition; Biogen expects the deal to be accretive in 2027 and generate at least $250 million in run-rate synergies exiting 2027.